Novavax rockets on news of COVID-19 vaccine deal with Sanofi

10 May 2024

French pharma major Sanofi (Euronext: SAN) says that, as part of its commitment to developing a diverse portfolio of best-in-class vaccines, it has entered into a co-exclusive licensing agreement with US biotech Novavax (Nasdaq: NVAX).

Shares of Novavax were up a 127.3% at $10.03 in pre-market trading this morning.

Sanofi is one of the world’s top producers of flu vaccines with sales of 2.7 billion euros ($2.9 billion) last year, but its early forays into the covid vaccines sector have not been particularly successful compared with jabs from the likes of Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) and Moderna (Nasdaq: MRNA). However, the deal with Novavax is a chance to develop a combination flu-Covid jab.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK